New chemical method to enhance drug discovery developed

A new chemical method ha been developed that enhances

“The ability to synthesise these compounds rapidly and stereochemical control open new possibilities for designing targeted therapies that combat cancer cells more effectively while minimizing side effects.”

By leveraging the unique properties of the t-BuSF reagent, researchers were able to explore previously inaccessible chemical space within the sulfur family, particularly in the S(IV) and S(VI) oxidation states.

This advancement has resulted in the creation of over 70 new chemical compounds, many of which have immediate applications in medicinal chemistry and the development of new pharmaceutical agents.

Lopchuk adds that this research has already been used to significantly improve the scalable synthesis of DFV890, an investigational compound from Novartis currently in clinical trials at Moffitt and other locations for myeloid diseases.

This study was supported by the National Institutes of Health, carried out by researchers at the Moffitt Cancer Center, and has been published in Nature Communications.